Viralytics: Eye-Catching MITCI Data
Edison | May 05, 2016 08:38AM ET
Impressive initial results from the MITCI Phase Ib trial suggest that Viralytics Ltd (AX:VLA) could push to the forefront of the crowded field of immune checkpoint inhibitor (ICI) combination therapies. The first six melanoma patients treated with Cavatak in combination with Yervoy (ipilimumab) experienced a higher response rate (67%) and lower serious adverse event rate (9%) than other prominent ICI combination therapies. These encouraging initial data bode well for the ongoing Phase Ib trials of Cavatak in combination with Merck’s Keytruda in melanoma, lung and bladder cancer, and are likely to be of great interest to potential partners. We increase our valuation to A$272m (A$192m previously), or A$1.15 per share (was A$1.04).
Impressive preliminary response rate in MITCI
Preliminary results from the ongoing MITCI Phase Ib trial of Cavatak in combination with Yervoy (ipilimumab) in patients with advanced melanoma were presented at AACR in April. Of the 11 patients treated to date only one (9%) has experienced a serious (grade 3 or higher) adverse event. Four of the six (67%) patients who have been assessed for tumour response have experienced confirmed objective responses (including two complete responses), compared to response rates of 28% and 11% reported for Cavatak and Yervoy, respectively, as single agents and response rates of 56% and 60% for Yervoy in combination with Imlygic (T-vec) and Opdivo. Separately, an update on the CAPRA trial of intra-tumoural injection of Cavatak in combination with the anti-PD1 ICI Keytruda is expected in H216.
To read the entire report Please click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.